Monitoring and AE Management Strategies with Fruquintinib in CRC
Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.
Stay updated with breaking news from Adverse Effect Management. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Margot O'Neill, PA-C, MHS, and Michael Leung, PharmD, discuss the monitoring and adverse effect management strategies for patients with colorectal cancer who receive fruquintinib.
This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.
Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.